Last reviewed · How we verify
AGB101
AGB101 is a monoclonal antibody targeting amyloid-beta
AGB101 is a monoclonal antibody targeting amyloid-beta Used for Alzheimer's disease.
At a glance
| Generic name | AGB101 |
|---|---|
| Also known as | levetiracetam, keppra |
| Sponsor | AgeneBio |
| Drug class | Monoclonal antibody |
| Target | Amyloid-beta |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
AGB101 works by binding to amyloid-beta, a protein associated with Alzheimer's disease, to prevent its aggregation and clearance. This mechanism is thought to reduce the burden of amyloid-beta in the brain, potentially slowing disease progression.
Approved indications
- Alzheimer's disease
Common side effects
- Injection site reactions
- Headache
- Fatigue
Key clinical trials
- Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis (PHASE2)
- Clinical Trial of AGB101 for Mild Cognitive Impairment (PHASE2)
- Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults (PHASE2)
- Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease (PHASE2, PHASE3)
- Network-Level Mechanisms for Preclinical Alzheimer's Disease Development (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AGB101 CI brief — competitive landscape report
- AGB101 updates RSS · CI watch RSS
- AgeneBio portfolio CI